Region Sjaelland

The Hjertemedicinsk Forskningsenhed in Holbæk conducts studies aimed at improving treatment and prevention of heart‑related conditions. Trials explore new therapies for atherosclerotic cardiovascular disease, strategies to reduce risk of stroke in patients with atrial fibrillation, and interventions during in‑hospital cardiac arrest. The goal is to evaluate effectiveness of innovative drugs and emergency measures to lower mortality and complications.

• Evaluation of novel anticoagulant asundexian versus standard therapy
• Assessment of lipoprotein‑targeting agent olpasiran for reducing cardiovascular events
• Investigation of sodium bicarbonate use in cardiac arrest resuscitation
• Study of outcomes after coronary events in ASCVD patients

Researchers at the site collaborate with local hospitals to bring cutting‑edge cardiovascular care to patients across Denmark.

At the same department, investigators focus on weight management and metabolic health, testing new approaches for children with obesity and adults struggling with excess weight. One study examines the impact of a weekly injection of semaglutide combined with lifestyle changes on body‑mass reduction in young patients. The overarching aim is to identify safe and effective options to combat obesity and its related complications.

• Semaglutide therapy for pediatric obesity
• Lifestyle‑enhanced pharmacologic weight loss programs
• Monitoring of metabolic markers during treatment
• Strategies to prevent progression to cardiovascular disease

The clinic’s multidisciplinary team integrates nutrition, endocrinology, and cardiology expertise to support participants throughout the trials.